Prakt. lékáren. 2007; 3(6): 284-286

Rizika spojená s podáváním inhibitorů angiotenzin-konvertujícího enzymu

MUDr. František Kulič
Interní oddělení, Masarykova nemocnice, Ústí nad Labem

Jsou popsáni dva pacienti se závažnou hyperkalémií, která vznikla při kombinaci inhibitoru angiotenzin-konvertujícího enzymu se spironolaktonem.

Keywords: inhibitory angiotenzin-konvertujícího enzymu, spironolakton, hyperkalémie

Published: January 20, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kulič F. Rizika spojená s podáváním inhibitorů angiotenzin-konvertujícího enzymu. Praktické lékárenství. 2007;3(6):284-286.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Ahmed A et al. Digoxin and reduction in mortality and hospitalisation in heart failure: a comprehensive post hoc analysis of the DIG trail. Eur Heart J 2006; 27: 178-186. Go to original source... Go to PubMed...
    2. Aust Adv Drug Reactions Bull 2005; 24: 7-8.
    3. Bozkurt B et al. Complications of inappropriate use of spironolactone in heart failure. J Am Coll Cardiol 2003; 41: 211-214. Go to original source... Go to PubMed...
    4. Juurlink et al. Rates of hyperkalemia after publication of the RALES. Arch Inter Med 2004; 351: 543-551. Go to original source...
    5. Pitt B et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-1321. Go to original source... Go to PubMed...
    6. Pitt B et al The Effects of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709-717.
    7. Standardy péče o diabetes mellitus 2. typu, schválené výborem České diabetologické společnosti dne 18. 5. 2007.
    8. Špinar J et al Doporučení pro diagnostiku a léčbu chronického srdečního selhání ČKS 2006. Cor Vasa 2007;49: K5-K34.
    9. The digitalis investigation group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997; 336: 525-533.
    10. Withering W An account of the foxglove and some of its medical uses; with practical remarks on the dropsy, and some other diseases. Publ Swinney, Birmingham 1785.
    11. Wrenger E et al Interaction od spironolactone with ACE inhibitors or angiotensin receptor blockers. BMJ 2003; 327: 147-149. Go to PubMed...

    Return to the content


    Pharmacy for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.